v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2025
Mar. 31, 2024
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenue $ 0   $ 200,000 $ 50,000
Operating expenses:        
Research and development 1,906,000 $ 904,000 5,088,000 4,045,000
General and administrative 2,973,000 2,722,000 8,516,000 9,230,000
Total operating expenses 4,879,000 3,626,000 13,604,000 13,275,000
Operating loss (4,879,000) (3,626,000) (13,404,000) (13,225,000)
Other income (expense):        
Interest expense (54,000) (52,000) (168,000) (112,000)
Interest income 72,000 43,000 358,000 140,000
Gain on sale of intellectual property   1,000,000   1,000,000
Total other income 18,000 991,000 190,000 1,028,000
Net loss from continuing operations (4,861,000) (2,635,000) (13,214,000) (12,197,000)
Loss from discontinued operations   (537,000)   (4,932,000)
Net loss $ (4,861,000) $ (3,172,000) $ (13,214,000) $ (17,129,000)
Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations $ (0.49) $ (0.71) $ (1.44) $ (5.43)
Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations (0.49) (0.71) (1.44) (5.43)
Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations 0.00 (0.14)   (2.19)
Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations 0.00 (0.14) 0.00 (2.19)
Loss per common share attributable to iBio, Inc. stockholders - basic - total (0.49) (0.85) (1.44) (7.62)
Loss per common share attributable to iBio, Inc. stockholders - diluted - total $ (0.49) $ (0.85) $ (1.44) $ (7.62)
Weighted-average common shares outstanding - basic 9,862 3,713 9,202 2,247
Weighted-average common shares outstanding - diluted 9,862 3,713 9,202 2,247